PermaLink™
Glythera's PermaLink™ technology is a controlled, stable conjugation platform composed of a portfolio of linker designs. PermaLink™ can be employed for the selective and stable functionalization and conjugation of various cargos to proteins and peptides. Due to its increased stability and selectivity, PermaLink™ offers significant benefits in the development of next generation biologics: - Antibody Drug Conjugates - Conjugate vaccines - PEGylation PermaLink™ offers a number of other benefits including: - Comparative model system - Controlled Drug to Antibody Ratio (DAR) - Improved linker stability compared to maleimide based technologies - Comparable in vitro activity - Low immunogenic potential